Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × Modafinil × Clear all

Phase

Phase 3 3 Phase 2 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

cyclopia sequence 2 Head and Neck Neoplasms 2 Fatigue 2 Neoplasms 1 Lung Neoplasms 1 Laryngeal Diseases 1 Cognitive Dysfunction 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1

Interventions

pembrolizumab 44 Nivolumab 28 Gemcitabine 28 Paclitaxel 19 Cisplatin 18 Ipilimumab 14 Carboplatin 14 Cyclophosphamide 13 Capecitabine 12 Dexamethasone 10 Bevacizumab 10 Irinotecan 9 Docetaxel 9 Albumin-Bound Paclitaxel 9 130-nm albumin-bound paclitaxel 9 spartalizumab 8 cemiplimab 8 Pemetrexed 8 Sorafenib 7 Rituximab 7 Cetuximab 7 fludarabine 6 Temozolomide 6 Taxes 6 Radiotherapy 6 Leucovorin 6 Fluorouracil 6 Azacitidine 6 Ascorbic Acid 6 lenvatinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05333250 2026-01-13

MODIFY

Ottawa Hospital Research Institute

Phase 1/2 Recruiting

Fatigue, Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡